This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Lovastatin Study Groups I Through IV

Arch Intern Med. 1993;153(9):1079-1087.

Abstract
Background
Inhibitors of hydroxymethylglutaryl coenzyme A reductase are widely used to treat hypercholesterolemia. They have a good short- to medium-term safety profile, but long-term safety data are limited.

Methods
Seven hundred forty-five patients with severe hypercholesterolemia (mean baseline plasma cholesterol level on diet, 9.3 mmol/L [360 mg/dL]) were treated with lovastatin for a median duration of 5.2 years. Their mean age at baseline was 50 years, 68% were male, 60% had familial hypercholesterolemia, and 42% had a history of coronary heart disease. Seventy-seven percent of patients had titrations of lovastatin to 80 mg/d, and 58% took other lipid-lowering agents, usually bile acid sequestrants, concomitantly.

Results
The mean changes at 5 years in total, low-density lipoprotein, and high-density lipoprotein cholesterol were -35%, -44%, and +14%, respectively. Eighty percent of patients completed the study, 13% were unavailable for follow-up, 4% were discontinued due to adverse events unlikely to be related to lovastatin, and 3% (21) were discontinued because of drug-attributable adverse events: marked but asymptomatic increase in aminotransferase values (10 patients), gastrointestinal disturbance (three patients), rash (two patients), myalgia (one patient), myopathy (two patients), arthralgia (one patient), insomnia (one patient), and weight gain (one patient). Sixteen patients died during the study, all of coronary disease. Of these, 14 had coronary heart disease at baseline. There were no deaths attributable to trauma, suicide, or homicide, and there were only 14cases of cancer (vs 21 expected). There was no evidence for an adverse effect on the lens.

Conclusions
Lovastatin is a generally well-tolerated and effective drug during long-term use.

(Arch Intern Med. 1993;153:1079-1087)

Author Affiliations
From the Lovastatin Study Groups.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Improvement in sleep apnoea associated with switch from simvastatin to pravastatin
Cham et al.
BMJ Case Reports 2009;2009:bcr0520091875-bcr0520091875.
ABSTRACT | FULL TEXT  

Lack of Efficacy of the Statins Atorvastatin and Lovastatin in Rodent Mammary Carcinogenesis
Lubet et al.
Cancer Prevention Research 2009;2:161-167.
ABSTRACT | FULL TEXT  

Tocotrienols Potentiate Lovastatin-Mediated Growth Suppression In Vitro and In Vivo
McAnally et al.
Exp. Biol. Med. 2007;232:523-531.
ABSTRACT | FULL TEXT  

Statin use and breast cancer: prospective results from the Women's Health Initiative.
Cauley et al.
JNCI J Natl Cancer Inst 2006;98:700-707.
ABSTRACT | FULL TEXT  

Use of Statins and Breast Cancer: A Meta-Analysis of Seven Randomized Clinical Trials and Nine Observational Studies
Bonovas et al.
JCO 2005;23:8606-8612.
ABSTRACT | FULL TEXT  

The Potential Role of HMG-CoA Reductase Inhibitors in Pediatric Nephrotic Syndrome
Prescott et al.
The Annals of Pharmacotherapy 2004;38:2105-2114.
ABSTRACT | FULL TEXT  

Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism
Shibata et al.
Carcinogenesis 2004;25:1887-1898.
ABSTRACT | FULL TEXT  

Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention
Mo and Elson
Exp. Biol. Med. 2004;229:567-585.
ABSTRACT | FULL TEXT  

Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction
Sipe et al.
The Annals of Pharmacotherapy 2003;37:808-811.
ABSTRACT | FULL TEXT  

Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models
Shibata et al.
Carcinogenesis 2003;24:453-459.
ABSTRACT | FULL TEXT  

Association of HMG-CoA Reductase Inhibitors with Neuropathy
Backes and Howard
The Annals of Pharmacotherapy 2003;37:274-278.
ABSTRACT | FULL TEXT  

Alpha Tocopheryl Succinate, Retinoic Acid and Polar Carotenoids Enhanced the Growth-Inhibitory Effect of a Cholesterol-Lowering Drug on Immortalized and Transformed Nerve Cells in Culture
Kumar et al.
J. Am. Coll. Nutr. 2001;20:628-636.
ABSTRACT | FULL TEXT  

Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase
Rao et al.
Proc. Natl. Acad. Sci. USA 1999;96:7797-7802.
ABSTRACT | FULL TEXT  

Plasma and Hepatic Cholesterol and Hepatic Activities of 3-Hydroxy-3-methyl-glutaryl-CoA Reductase and Acyl CoA: Cholesterol Transferase Are Lower in Rats Fed Citrus Peel Extract or a Mixture of Citrus Bioflavonoids
Bok et al.
J. Nutr. 1999;129:1182-1185.
ABSTRACT | FULL TEXT  

Forecasting Patient Outcomes in the Management of Hyperlipidemia
Brier et al.
Arch Intern Med 1999;159:569-575.
ABSTRACT | FULL TEXT  

An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor
Black et al.
Arch Intern Med 1998;158:577-584.
ABSTRACT | FULL TEXT  

Efficacy of Low-Dose Cholesterol-Lowering Drug Therapy in Men With Moderate Hypercholesterolemia
Denke and Grundy
Arch Intern Med 1995;155:393-399.
ABSTRACT  

Hypercholesterolemia in Postmenopausal Women: Metabolic Defects and Response to Low-Dose Lovastatin
Arca et al.
JAMA 1994;271:453-459.
ABSTRACT  

Blood Cholesterol Measurement in Young Adults
Tobert
JAMA 1993;270:936-936.
ABSTRACT